+34 620 10 75 37info@nanbiosis.com

Posts Taged point-of-care-device

Label-free bacteria quantification in blood plasma by a bioprinted microarray based interferometric point-of-care device

Prof Laura Lechuga, Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit is coauthor of an article publish by ACS Sonsors that shows a portable and autonomous device based on optical interferometry that, when used with specialized nanoplasmonic, can detect directly bacterial cells of the patient’s blood plasma.

The work demonstrates the potential of a microarray based POC device for bacteria quantification. The contribution of NANBIOSIS, in particular Unit 4, has been fundamental by providing the  molecular printers necessary for the generation of the biofunctionalized specific microarrayed chips used for the bacteria detection.

P. Dey, N. Fabri-Faja, O. Calvo-Lozano, R. Terborg, A. Belushkin, F. Yesilköy, A. Fàbrega, J. C. Ruiz-Rodriguez, R. Ferrer, J. J. González-López, M. C. Estévez, H. Altug, V. Pruneri, L. M. Lechuga. Label-free bacteria quantification in blood plasma by a bioprinted microarray based interferometric point-of-care device. ACS Sens., 20194 (1), pp 52–60 DOI: 10.1021/acssensors.8b00789

Read More

Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma

As a result of the collaboration carried aout by two units of NANBIOSIS, U4. Biodeposition and Biodetection Unit and U2. Custom Antibody Service (CAbS), it has been developed a compact and simple nanoplasmonic sensing device based on gold nanodisks for the rapid monitoring of acenocoumarol, using highly specific polyclonal antibodies produced against the drug Acenocoumarol (Sintrom®) which implies:

  • A label-free nanoplasmonic device for the rapid monitoring of acenocoumarol in plasmaD.
  • Direct quantification in real time requiring low sample volume is achieved.
  • Non-specific interferences from plasma are minimized using the developed methodology.
  • Excellent accuracy has been observed measuring blind plasma samples.
  • Potential to be implemented as a POC device in decentralized settings.

 

The research details have been published in the article authored by E. CristinaPeláezM.-CarmenEstevezAlejandroPortelaJ.-PabloSalvadorM.-PilarMarco and Laura M.Lechuga, “Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma, Biosensors and Bioelectronic, 119, 2018, 149-155 – DOI: https://doi.org/10.1016/j.bios.2018.08.011

 

Read More